We urgently need biomarkers that are sensitive, objective, and practical. Eye-movement measures are ready to fill this gap, not as distant innovations, but as tools available today.Drug development for neurodegenerative diseases is struggling with one of its most intractable barriers: the slow, variable, and subjective nature of clinical endpoints Traditional assessment scales, whether in Parkinson’s […]
